Aspire Private Capital’s Editas Medicine EDIT Stock Holding History

Aspire Private Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50	Closed	-$1K	–	624
2022 Q2	$1K	Hold	50	–	–	﹤0.01%	535
2022 Q1	$1K	Hold	50	–	–	﹤0.01%	540
2021 Q4	$1K	Hold	50	–	–	﹤0.01%	578
2021 Q3	$2K	Hold	50	–	–	﹤0.01%	484
2021 Q2	$3K	Buy	+50	New	+$1.85K	﹤0.01%	449

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Aspire Private Capital's EDIT Position: Q3 2022 in Review

Aspire Private Capital sold out of Editas Medicine (EDIT) in Q3 2022, closing a stake of 50 shares — an estimated $1K sold.

Aspire Private Capital first reported a position in EDIT in Q2 2021 and held it in 5 quarters. The position peaked at $3K in Q2 2021. 264 funds tracked by Wall St. Rank hold EDIT as of Q3 2022.

Aspire Private Capital reported no remaining Editas Medicine position as of Q3 2022 after selling out during the quarter.
Aspire Private Capital sold 50 Editas Medicine shares in Q3 2022, an estimated $1K.
Aspire Private Capital first reported a position in Editas Medicine in Q2 2021 and held it in 5 quarters.
Aspire Private Capital's Editas Medicine position peaked at $3K in Q2 2021.
264 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2022.

Based on Aspire Private Capital's 13F filing for Q3 2022, filed 10 Nov 2022.